


Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently amended) A chemical compound having the formula (I)



wherein,

R₁ is selected from the group consisting of hydrogen, allyl of 1 to 6 carbon atoms, unsubstituted phenyl, and substituted phenyl;

R₂ is selected from the group consisting of H, alkene, un-substituted phenyl
~~phenol~~, and substituted phenyl; and pharmaceutically acceptable salts thereof.


Claim 2. (Original) The chemical compound according to claim 1, wherein at least one of R₁ and R₂ is hydrogen.

Claim 3. (Original) The chemical compound according to claim 1, wherein R₁ is hydrogen.

Claim 4. (Original) The chemical compound according to claim 1, wherein R₂ is hydrogen.

Claim 5. (Currently amended) The chemical compound of claim 1, wherein R₁ is hydrogen; and R₂ is hydrogen; ~~the compound having~~

formula (II):



and pharmaceutically acceptable salts thereof.

Claim 6. (Original) A method of preparing the chemical compound according to claim 1, comprising steps of:

contacting 3,4-methylenedioxybenzoylhydrazine with an equimolar amount of thiophene-2-carboxaldehyde; and recovering the compound.

Claim 7. (Original) The method according to claim 6, wherein said thiophene-2-carboxaldehyde is in a solvent and a catalyst is used.

Claim 8. (Original) The method according to claim 7, wherein said solvent is ethanol and said catalyst is hydrochloric acid.

Claim 9. (Currently amended) A method of treating congestive heart failure in a patient in need of treatment with a calcium sensitizer, comprising ~~the step of~~ administering a therapeutically effective amount of the compound of claim 5 ~~LASSBio-294~~.

Appl. No. 10/070,328
Reply to Office Action of November 14, 2005

Claim 10. (Original) The method of treating a patient according to claim 9, wherein the therapeutically effective amount of the compound is one that produces a plasma concentration of the compound of 1 μM to 100 μM .

Claim 11. (Original) The method of treating a patient according to claim 10, wherein the therapeutically effective amount is one that produces a plasma concentration of the compound of 10 μM to 50 μM .

Claims 12-15. (Canceled)

Claim 16. (Currently amended) A pharmaceutical composition comprising the compound of claim 5 ~~LASSBio-294~~ and pharmaceutically acceptable salts thereof.

Claim 17. (Original) The pharmaceutical composition of claim 16, further comprising pharmaceutically acceptable inactive ingredients, comprising diluents, carriers, solvents, disintegrants, lubricants, stabilizers, and coatings.

Claim 18. (Original) The pharmaceutical composition of claim 17, wherein the composition is formulated for oral administration.


Claim 19. (Currently amended) The pharmaceutical composition of claim 16 ~~[[15]]~~, wherein the composition is formulated for parenteral administration.

Claim 20. (Currently amended) A chemical composition comprising the compound of claim 5 ~~LASSBio-294~~ and a second peptide compound; said composition having the characteristic of producing at least 20% oral bioavailability of the compound ~~LASSBio-294~~ when taken orally by a patient.

Claim 21. (Currently amended) The composition of claim 19 wherein the second peptide compound is selected from the group consisting of dipeptides and tripeptides.

Claim 22. (Currently amended) A pharmaceutical composition, comprising [[a]] the compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

Claim 23. (Currently amended) A pharmaceutical composition, comprising [[a]] the compound of claim 2 ~~formula (III)~~



in combination with a pharmaceutically acceptable carrier.

Claim 24. (New) A pharmaceutical composition, comprising the compound of Claim 3 in combination with a pharmaceutically acceptable carrier.

Claim 25. (New) A pharmaceutical composition, comprising the compound of Claim 4 in combination with a pharmaceutically acceptable carrier.

Claim 26. (New) A method of treating congestive heart failure comprising administering a therapeutically effective amount of the compound of claim 3.

Claim 27. (New) A method of treating congestive heart failure, comprising administering a therapeutically effective amount of the compound of claim 4.